Together, we can stop cancer

Nanotargeting for cancer immunotherapy

NanoSYS Biologics is a new generation immune checkpoint nanotechnology based Company in the early stage that utilizes its proprietary CheckpointNanothera technology. CheckpointNanothera uses nanoparticles to treat cancer by targeting of immune checkpoints in the immune system instead of the tumor itself.

 
 

Experience

The Company focuses on multifunctional checkpoint blockade in cancer immunotherapy using new generation of nanoparticles.

Strategy

Using CheckpointNanothera platform will create a novel targeting approach for distinct immune checkpoints irrespective of their cellular localization for the fraction of the costs ofmonoclonal antibody development.

success

NanoSYS Biologic`s technology platform addresses fast growing cancer immunotherapy market, which will be worth of 119.39 billion of USD by 2021.

WE have expertise & proven track record

success is imminent

   





Our strategy for removal of immune tolerance is to elicit antitumour immunity in several thousands of leukocytes sufficient to induce potent anti-cancer response using multi-specific nanoparticles targeting potent immune checkpoint inhibitors irrespective of their cellular localization.

It is expected that nanotargeting will compromise regulatory T(reg) cell tolerance to tumour. Moreover, this novel targeting approach for distinct immune checkpoints is using highly versatile multi-specific nanoparticles  for the fraction of the costs of monoclonal antibody development.

This novel targeting approach could speed up development of combined immunotherapies significantly.

OUR unique

strategy

  • Task: A) Reducing costs of immune checkpoint therapy using multifunctional nanoparticles instead of monoclonal antibodies. B) Improve relatively low incidence of response in cancer patients using multifunctional nanoparticles targeting immune checkpoints in combinatorial fashion.
  •  Action: Aim of our project is to elicit antitumour immunity against melanoma via targeting inducible cAMP early repressor (ICER) in cytotoxic T lymphocyte antigen - 4 (CTLA-4) positive T cells using multifunctional nanoparticles loaded with anti-ICER RNAi decorated with oligopeptides spanning specific paratopes trapping CTLA-4.
  • Result: Nanoparticles navigated through these peptides are meant not only to guide ICER RNAi delivery into CTLA-4 positive T cells but also to serve as functional CTLA-4 blockade replacing ipilimumab - clinically proven monoclonal antibody against melanoma blocking CTLA-4.

previous

Projects

 

The molecular mechanisms of cyclic AMP in regulation of immunity and tolerance

Editorial (page 1 and 2)

 

 

Delivery material for siRNA therapeutics

 

Navigate delivery with REcognitionPeptide design

 

client

reviews

This is a testimonial. To edit this testimonial, highlight the text and replace it with your own fresh content. Moving this text widget is no problem. Simply drag and drop the widget to your area of choice. Use this space to highlight a raving review from a client.

Matt Brown

This is a testimonial. To edit this testimonial, highlight the text and replace it with your own fresh content. Moving this text widget is no problem. Simply drag and drop the widget to your area of choice. Use this space to highlight a raving review from a client.

Jack Smith

This is a testimonial. To edit this testimonial, highlight the text and replace it with your own fresh content. Moving this text widget is no problem. Simply drag and drop the widget to your area of choice. Use this space to highlight a raving review from a client.

Jane Doe

looking for a

solution?

NanoSYSBiologics@seznam.cz

Jablonecka 7/716

Prague, Czech Republic 19000

+420 722 950 013

© Copyright NanoSYS Biologics